Printer Friendly, PDF & Email

DUSA Pharmaceuticals fined $20.75 million for fudging dosage requirements

The U.S. Department of Justice and DUSA Pharmaceuticals Inc. (DUSA) agreed to settle False Claims Act allegations through a fine and a corporate integrity agreement that requires DUSA to implement reviews and procedures to prevent similar problems in the future.

This document is only available to members. Please log in or become a member.